Oral Selective Estrogen Receptor Downregulators (SERDs), a Breakthrough Endocrine Therapy for Breast Cancer
Open accessAbstract
Drugs that inhibit estrogen receptor alpha (ERα) or that block the production of estrogens remain frontline interventions in the treatment and management of breast cancer at all stages. However, resistance to endocrine therapies, especially in the setting of advanced disease, remains an impediment to durable clinical responses. Although the mechanisms underlying resistance to existing agents are complex, preclinical studies suggest that selective estrogen receptor downregulators (SERDs), molecules which eliminate ERα expression, may have particular utility in the treatment of breast cancers that have progressed on tamoxifen and/or aromatase inhibitors. The discovery and development of orally bioavailable SERDs provide the opportunity to evaluate the utility of eliminating ERα expression in advanced metastatic breast cancers.
AI snapshot
Written from the paper’s full text.
TL;DR
This perspective argues that orally bioavailable selective estrogen receptor downregulators (SERDs) represent a promising advance for ERα-positive breast cancer that has progressed on tamoxifen or aromatase inhibitors, because they eliminate ERα rather than merely antagonizing it. It frames GDC-0810 (ARN-810), described by Lai et al. in the same issue, as the most advanced next-generation oral SERD and outlines open questions about its clinical utility.
Key findings
- Resistance to tamoxifen is now attributed to changes in coregulator expression/activity that let tamoxifen act as an agonist, rather than to ERα loss, drug metabolism, or MDR1 efflux; ligand-independent ERα activation reduces SERM antagonist efficacy but leaves SERD sensitivity unaffected.
- Up to 20% of tumors in metastatic, endocrine-resistant breast cancer are reported to contain activating mutations in the receptor, and preclinical studies support SERDs as a viable approach for these tumors.
- GW5638 is a prodrug converted to the more potent metabolite GW7604; cross-species microsome profiling found only ~16% conversion in human liver microsomes, a liability mitigated in the GDC-0810 series by modifications that increased potency and removed the primary glucuronidation site.
- In the Paloma 3 trial, combining the cdk4/6 inhibitor palbociclib with fulvestrant produced an improvement in progression-free survival (10 months) versus fulvestrant plus placebo in women with ER-positive metastatic breast cancer.
Methods
- Design: a narrative perspective/commentary in the Journal of Medicinal Chemistry; no primary experimental data are reported.
- Data: synthesis of prior literature and clinical/preclinical reports, plus discussion of the companion paper by Lai et al. identifying GDC-0810.
- Main analysis: conceptual review of ER pharmacology (conformation-based compound profiling, coregulator biology), the history of fulvestrant and GW5638/GW7604, and the development path of oral SERDs.
Limitations
- Stated: data describing the activity of GDC-0810 on ERα under conditions where it is constitutively active are missing from Lai et al.; the extent to which elimination of the need for metabolic activation contributes to clinical activity remains to be determined; whether SERDs have any therapeutic advantage over high-affinity competitive ERα antagonists without SERD activity remains unresolved; results of clinical trials of pipendoxifene (ERA924) and acolbifene (EM652) were never published, so the criteria for their discontinuation are unclear.
- Evident from the text: as a commentary, it presents no new experimental data, and its claims about GDC-0810's clinical value rest on trials described as ongoing and eagerly awaited rather than completed.
Model-written summary. Check it against the paper before relying on it.
Integrity signals
Registry
Cites
Statistics
Claims the paper makes
0 of 29 cited sources checked · 0 supported · 0 flagged
- Premisecitation
Upon binding tamoxifen, ERα adopts a unique conformation that presents protein-protein interaction surfaces required for its partial agonist activity.
“Evidence in support of this model came from structural studies that revealed that upon binding tamoxifen, ERα adopted a unique conformation that resulted in the presentation of protein-protein interaction surfaces required for its partial agonist activity.12, 13”
Quote in the paperSubstantial claim0 of 2 sources checked - Premisecitation
Resistance to tamoxifen results from changes in the expression or activity of coregulators that enable tamoxifen to manifest agonist activity.
“it is now believed that resistance to tamoxifen results from changes in the expression (or activity) of coregulators that enable tamoxifen to manifest agonist activity11.”
Quote in the paperSubstantial claim0 of 1 sources checked- cites [11] Musgrove E. A., 2009, Nat. Rev. Cancer source
Not checked in the free run.
- Interpretationnone given
It is unlikely that mTOR or cdk4/6 inhibitors will have as significant an impact on the pharmacotherapy of ER-positive breast cancer as drugs that interfere with the estrogen signaling axis.
“Notwithstanding the recent clinical success of these newer targeted therapies, it is unlikely that they will have as significant an impact on the pharmacotherapy of estrogen receptor (ER) positive breast cancer as drugs that interfere with the estrogen signaling axis.”
Quote in the paperNot a substantial claim- Rests on an assumption: ERα remains engaged in advanced disease, contributes to disease pathogenesis, and remains a viable therapeutic target.
- Premisecitation
The functional activity of the same ER-ligand complex can differ between cells because coregulator activity differs between cells.
“Thus, the same receptor-ligand complex can have completely different activities in different cells.8”
Quote in the paperSubstantial claim0 of 1 sources checked- cites [8] McDonnell D. P., 2010, Curr. Opin. Pharmacol. source
Not checked in the free run.
- Premisecitation
Preclinical studies suggest that SERDs may have particular utility in treating breast cancers that have progressed on tamoxifen and/or aromatase inhibitors.
“preclinical studies suggest that selective estrogen receptor downregulators (SERDs), molecules which eliminate ERα expression, may have particular utility in the treatment of breast cancers that have progressed on tamoxifen and/or aromatase inhibitors.”
Quote in the paperSubstantial claim0 of 1 sources checked- cites [7] source
Not checked in the free run.
- Rests on an assumption: ERα remains engaged in advanced disease, contributes to disease pathogenesis, and remains a viable therapeutic target.
- Premisecitation
GDC-0810 is equivalent to GW5638 in its ability to degrade ERα.
“The molecule selected for development, GDC-0810, has significantly improved exposure over benchmark compounds in animals, was equivalent to GW5638 in its ability to degrade ERα, and maintained the ability to inhibit the growth of tumors in a clinically relevant xenograft model of tamoxifen resistance.”
Quote in the paperSubstantial claim0 of 1 sources checked- cites [7] source
Not checked in the free run.
- Premisecitation
The conversion of GW5638 to GW7604 is variable, with only ~16% conversion observed in human liver microsomes.
“Using cross-species microsome profiling, it was determined that the conversion of GW5638 to GW7604 was variable with only ~16% conversion observed in human liver microsomes.”
Quote in the paperSubstantial claim0 of 1 sources checked- cites [7] source
Not checked in the free run.
- Interpretationreasoning
Dual or multiple pathway inhibition may be required to realize the full potential of SERDs or SERMs.
“Thus, dual or multiple pathway inhibition may be required to realize the full potential of SERDs or SERMs.”
Quote in the paperSubstantial claim - Interpretationreasoning
Several new ER modulators at various stages of development will be effective enough to warrant their registration as monotherapies.
“In addition to GDC-0810, there are several new ER modulators at various stages of development and it is reasonable to expect, given the underlying science, that several of these will be effective enough to warrant their registration as monotherapies.”
Quote in the paperNot a substantial claim- Rests on an assumption: ERα remains engaged in advanced disease, contributes to disease pathogenesis, and remains a viable therapeutic target.
- Premisecitation
GDC-0810 maintains the ability to inhibit tumor growth in a clinically relevant xenograft model of tamoxifen resistance.
“The molecule selected for development, GDC-0810, has significantly improved exposure over benchmark compounds in animals, was equivalent to GW5638 in its ability to degrade ERα, and maintained the ability to inhibit the growth of tumors in a clinically relevant xenograft model of tamoxifen resistance.”
Quote in the paperSubstantial claim0 of 1 sources checked- cites [7] source
Not checked in the free run.
- Premisecitation
The carboxylic acid group in GW7604 directly interacts with the peptide backbone of ERα, inducing a conformational change that exposes a hydrophobic surface targeting the receptor for degradation.
“Crytallographic analysis of the ERα-GW7604 complex revealed that the carboxylic acid group in this compound (Table 1) was the key “warhead” and that its direct interaction with the peptide backbone of the receptor induced a conformational change that exposed a hydrophobic surface on the receptor that targeted it for degradation.16”
Quote in the paperSubstantial claim0 of 1 sources checked- cites [16] Wu Y. V. L., 2005, Mol. Cell source
Not checked in the free run.
- Premisecitation
GW5638 is a prodrug that is converted following oral delivery to its more potent metabolite GW7604.
“As noted in Lai et al, GW5638 is a prodrug that is converted following oral delivery to its more potent metabolite GW7604.7”
Quote in the paperSubstantial claim0 of 1 sources checked- cites [7] source
Not checked in the free run.
- Premisecitation
These mechanisms are thought to underlie resistance to both SERMs and aromatase inhibitors.
“These mechanisms are also thought to underlie resistance to both SERMs and to aromatase inhibitors.18”
Quote in the paperSubstantial claim0 of 1 sources checked- cites [18] Masamura S., 1995, J. Clin. Endocrinol. Metab.
Not checked in the free run.
- Interpretationreasoning
Tamoxifen-resistant cancers should be sensitive to ERα ligands that induce a conformational change that does not enable presentation of coregulator binding surfaces required for 17β-estradiol or tamoxifen agonist activity.
“It was implied therefore that tamoxifen resistant cancers should be sensitive to ERα ligands that induced a conformational change in the receptor that did not enable the presentation of coregulator binding surfaces required for 17β-estradiol or tamoxifen agonist activity (Figure 1).”
Quote in the paperSubstantial claim- Rests on an assumption: ERα remains engaged in advanced disease, contributes to disease pathogenesis, and remains a viable therapeutic target.
- Premisecitation
Up to 20% of tumors in metastatic, endocrine-resistant breast cancer contain activating mutations in the receptor.
“Further, it now appears that up to 20% of tumors in metastatic, endocrine resistant breast cancer contain activating mutations in the receptor”
Quote in the paperSubstantial claim0 of 1 sources checked- cites [19] Jeselsohn R., 2014, Clin. Cancer Res. source
Not checked in the free run.
- Premisecitation
There has been a dramatic increase in the incidence of breast cancer brain metastasis (BCBM) despite improved treatment of peripheral disease with tamoxifen and aromatase inhibitors.
“Whereas the treatment (and management) of peripheral disease has improved substantially with the advent of tamoxifen and aromatase inhibitors, there has been a dramatic increase in the incidence of BCBM 20.”
Quote in the paperSubstantial claim0 of 1 sources checked- cites [20] Freedman R. A., 2012, Curr. Breast Cancer Rep. source
Not checked in the free run.
- Premisecitation
Inhibition of MAPK or Src in human tumor explants results in an increase in ERα protein.
“Likewise in human tumor explants it has been shown that inhibition of MAPK or Src results in an increase in ERα protein.23”
Quote in the paperSubstantial claim0 of 1 sources checked- cites [23] Creighton C. J., 2006, Cancer Res. source
Not checked in the free run.
- Premisecitation
The prevalence of ERα-positive BCBM is considerably higher than expected.
“However, more recent studies have indicated that the prevalence of ERα-positive BCBM is considerably higher than expected 21.”
Quote in the paperSubstantial claim0 of 1 sources checked- cites [21] Duchnowska R., 2012, Breast Cancer Res. source
Not checked in the free run.
- Interpretationreasoning
It is likely that the true potential of GDC-0810 and like compounds will be observed in the context of drug combinations that target ERα and other signaling pathways.
“However, it is likely that the true potential of GDC-0810, and like compounds, will be observed in the context of drug combinations that target ERα and other signaling pathways.”
Quote in the paperNot a substantial claim- Rests on an assumption: The Paloma 3 clinical trial reported that combining palbociclib with fulvestrant improved progression-free survival (10 months) compared to fulvestrant plus placebo in women with ER-positive metastatic breast cancer.
- Premisecitation
Increased expression of coregulators or hyperactivation of signaling pathways that impact the ER-coregulator complex enables the receptor to activate target gene transcription in a ligand-independent manner.
“Notably, it has been demonstrated in the past in a variety of models that increased expression of coregulators or hyperactivation of signaling pathways that impact the ER-coregulator complex enables the receptor to activate target gene transcription in a ligand independent manner.”
Quote in the paperSubstantial claim0 of 1 sources checked- cites [18] Masamura S., 1995, J. Clin. Endocrinol. Metab.
Not checked in the free run.
- Premisecitation
Preclinical studies support the idea that SERDs are a viable approach to treat patients whose tumors harbor activating ERα mutations.
“and the preclinical studies presented thus far support the idea that SERDs are viable approach to treat patients whose tumors harbor these mutations.19”
Quote in the paperSubstantial claim0 of 1 sources checked- cites [19] Jeselsohn R., 2014, Clin. Cancer Res. source
Not checked in the free run.
- Rests on an assumption: ERα remains engaged in advanced disease, contributes to disease pathogenesis, and remains a viable therapeutic target.
- Premisecitation
The mechanisms underlying the SERD activity of different chemical classes of SERDs are not the same.
“From what is known, thus far, it appears as if the mechanisms underlying the SERD activity of these different classes of compounds are not the same. 26, 27”
Quote in the paperNot a substantial claim0 of 2 sources checked - Premisecitation
GDC-0810 has significantly improved exposure over benchmark compounds in animals.
“The molecule selected for development, GDC-0810, has significantly improved exposure over benchmark compounds in animals, was equivalent to GW5638 in its ability to degrade ERα, and maintained the ability to inhibit the growth of tumors in a clinically relevant xenograft model of tamoxifen resistance.”
Quote in the paperSubstantial claim0 of 1 sources checked- cites [7] source
Not checked in the free run.
- May combine two claims. 7
May combine two claims.
PremisecitationGDC-0810 (ARN-810) is the most advanced of the next generation SERDs and is currently being evaluated in clinical trials in breast cancer patients who have progressed on standard endocrine therapy.
“The orally bioavailable drug described by Lai et al in this issue, GDC-0810 (ARN-810), is the most advanced of the next generation SERDs and is currently being evaluated in clinical trials in breast cancer patients who have progressed on standard endocrine therapy.7”
Quote in the paperSubstantial claim0 of 1 sources checked- cites [7] source
Not checked in the free run.
- Rests on an assumption: ERα remains engaged in advanced disease, contributes to disease pathogenesis, and remains a viable therapeutic target.
May combine two claims.
PremisecitationFulvestrant has significant pharmaceutical liabilities (requiring intramuscular injection) which have negatively impacted its widespread use.
“Unfortunately, fulvestrant has significant pharmaceutical liabilities (requiring intramuscular injection) which have negatively impacted its widespread use.6”
Quote in the paperSubstantial claim0 of 1 sources checked- cites [6] Robertson J. F. R., 2007, Oncologist source
Not checked in the free run.
May combine two claims.
InterpretationcitationThere has been considerable progress of late in developing orally bioavailable SERDs and it is likely that these will have a significant impact on the pharmacotherapy of breast cancer.
“In conclusion, as evidenced by the studies presented in Lai et al, there has been considerable progress of late in developing orally bioavailable SERDs and it is likely that these will have a significant impact on the pharmacotherapy of breast cancer.”
Quote in the paperSubstantial claim0 of 1 sources checked- cites [7] source
Not checked in the free run.
- Rests on an assumption: ERα remains engaged in advanced disease, contributes to disease pathogenesis, and remains a viable therapeutic target.
May combine two claims.
PremisecitationGW5638 and its metabolite GW7604 inhibit 17β-estradiol-dependent growth of ERα-positive breast tumor xenografts and are effective in tumor models of tamoxifen resistance.
“Significantly, these drugs inhibited 17β-estradiol-dependent growth of ERα-positive breast tumor xenografts and more importantly were shown to be extremely effective in tumor models of tamoxifen resistance.”
Quote in the paperSubstantial claim0 of 2 sources checked- cites [14] Connor C. E., 2001, Cancer Res.
Not checked in the free run.
- cites [15] Willson T. M., 1994, J. Med. Chem. source
Not checked in the free run.
May combine two claims.
InterpretationreasoningLigand-independent activation of ERα reduces the antagonist efficacy of SERMs while sensitivity to SERDs is unaffected.
“Ligand-independent activation of ERα reduces the antagonist efficacy of SERMs while the sensitivity to SERDs is unaffected.”
Quote in the paperSubstantial claim- Rests on an assumption: ERα remains engaged in advanced disease, contributes to disease pathogenesis, and remains a viable therapeutic target.
May combine two claims.
PremisecitationThe aromatase enzyme (cyp19) is expressed in brain and the ERα-partial agonist 27-hydroxycholesterol is the most abundant oxysterol in brain.
“This is of concern as the aromatase enzyme (cyp19) is expressed in brain and considering that the ERα-partial agonist 27-hydroxycholesterol is the most abundant oxysterol in brain.22”
Quote in the paperSubstantial claim0 of 1 sources checked- cites [22] Simpson E. R., 2003, J. Steroid Biochem. Mol. Biol. source
Not checked in the free run.
May combine two claims.
PremisecitationResistance to HER2/EGFR inhibitors and to PI3K inhibitors is associated with increased intratumoral expression of ERα, and in relevant models such resistance can be reversed by the SERD fulvestrant.
“It has been shown for instance that resistance to HER2/EGFR inhibitors and to PI3K inhibitors is associated with increased intratumoral expression of ERα and in relevant models it has been shown that such resistance can be reversed by the SERD fulvestrant.23-25”
Quote in the paperSubstantial claim0 of 3 sources checked
The paper relies on this without support.
Resistance to endocrine therapies, especially in advanced disease, remains an impediment to durable clinical responses.
“However, resistance to endocrine therapies, especially in the setting of advanced disease, remains an impediment to durable clinical responses.”
The paper relies on this without support.
ERα remains engaged in advanced disease, contributes to disease pathogenesis, and remains a viable therapeutic target.
“It is now well established that ERα remains engaged in advance disease, contributes to disease pathogenesis, and remains a viable therapeutic target.”
The paper relies on this without support.
The Paloma 3 clinical trial reported that combining palbociclib with fulvestrant improved progression-free survival (10 months) compared to fulvestrant plus placebo in women with ER-positive metastatic breast cancer.
“Indeed, the recent results of the Paloma 3 clinical trial were very encouraging as it was reported that regimens in which the cdk4/6 inhibitor (palbociclib) and fulvestrant were combined demonstrated an impressive improvement in progression free survival (10 months) when compared to fulvestrant plus placebo in women with ER positive metastatic breast cancer.”
The paper relies on this without support.
There is little data on the ability of existing ER modulators and aromatase inhibitors to cross the blood-brain barrier.
“There is little data on the ability of existing ER modulators and aromatase inhibitors to cross the blood brain barrier (BBB) and thus there is considerable interest in evaluating brain penetrant SERDs or SERMs in patients with BCBM.”
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The ER in breast cancer and the AR in prostate cancer are the leading examples of targets with well-characterized biological and biochemical properties, clinically validated roles in disease, and previously established clinical efficacy for their inhibition.
“The ER in breast cancer38,39 and the AR in prostate cancer33 are the leading examples of such targets.”
From PROTAC targeted protein degraders: the past is prologue (2022) · cites this paper as [38]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
Each contradiction between two passages listed here was confirmed by an independent check.
Inconsistent AZD compound identifier
MinorThe paper identifies the SERD in development as AZD9496, but the conclusion calls it AZD9694. The text does not explain whether these are different compounds.
“additional compounds with structural similarity to GW5638 (e.g. AZD9496) are also currently making their way through clinical development.”
“Given that GDC-0810 and AZD9694 are already in clinical trials”
Cites
Everolimus in Postmenopausal Hormone-Receptor–Positive Advanced Breast Cancer
Baselga, J., Campone, M., Piccart, M., Burris, H. A., Rugo, H. S., Sahmoud, T., Noguchi, S., Gnant, M., Pritchard, K. I., Lebrun, F., et al. (2012) · New England Journal of Medicine · doi:10.1056/nejmoa1109653 · Cited by 2,863 · see citing works
Shiau, A. K., Barstad, D., Loria, P. M., Cheng, L., Kushner, P. J., Agard, D. A., & Greene, G. L. (1998) · Cell · doi:10.1016/s0092-8674(00)81717-1 · Cited by 2,726 · see citing works
Biological determinants of endocrine resistance in breast cancer
Musgrove, E. A., & Sutherland, R. L. (2009) · Nature reviews. Cancer · doi:10.1038/nrc2713 · Cited by 1,254 · see citing works
Effects of Tamoxifen on Bone Mineral Density in Postmenopausal Women with Breast Cancer
Love, R. R., Mazess, R. B., Barden, H. S., Epstein, S., Newcomb, P. A., Jordan, V. C., Carbone, P. P., & DeMets, D. L. (1992) · New England Journal of Medicine · doi:10.1056/nejm199203263261302 · Cited by 1,127 · see citing works
Sources of estrogen and their importance
Simpson, E. R. (2003) · The Journal of Steroid Biochemistry and Molecular Biology · doi:10.1016/s0960-0760(03)00360-1 · Cited by 936 · see citing works
Jeselsohn, R., Yelensky, R., Buchwalter, G., Frampton, G., Meric-Bernstam, F., Gonzalez-Angulo, A. M., Ferrer-Lozano, J., Perez-Fidalgo, J. A., Cristofanilli, M., Gómez, H., et al. (2014) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-13-2332 · Cited by 674 · see citing works
Bosch, A., Li, Z., Bergamaschi, A., Ellis, H., Toska, E., Prat, A., Tao, J. J., Spratt, D. E., Viola, N. T., Castel, P., et al. (2015) · Science Translational Medicine · doi:10.1126/scitranslmed.aaa4442 · Cited by 432 · see citing works
Contrasting actions of tamoxifen on endometrial and breast tumor growth in the athymic mouse.
Gottardis, M. M., Robinson, S. P., SATYASWAROOP, P. G., & Jordan, V. C. (1988) · PubMed · Cited by 422 · see citing works
Xia, W., Bacus, S., Hegde, P., Husain, I., Strum, J., Liu, L., Paulazzo, G., Lyass, L., Trusk, P., Hill, J., et al. (2006) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0602468103 · Cited by 374 · see citing works
Peptide Antagonists of the Human Estrogen Receptor
Norris, J. D., Paige, L. A., Christensen, D. J., Chang, C., Huacani, M. R., Fan, D., Hamilton, P. T., Fowlkes, D. M., & McDonnell, D. P. (1999) · Science · doi:10.1126/science.285.5428.744 · Cited by 367 · see citing works
Self-citationEstrogen deprivation causes estradiol hypersensitivity in human breast cancer cells
Masamura, S., Santner, S. J., Heitjan, D. F., & Santen, R. J. (1995) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jcem.80.10.7559875 · Cited by 307 · see citing works
Investigation of a new pure antiestrogen (ICI 182780) in women with primary breast cancer.
DeFriend, D. J., Howell, A., Nicholson, R. I., Anderson, E., Dowsett, M., Mansel, R. E., Blamey, R. W., Bundred, N. J., Robertson, J. F. R., & Saunders, C. M. (1994) · PubMed · Cited by 291 · see citing works
Lai, A. G., Kahraman, M., Govek, S. P., Nagasawa, J. Y., Bonnefous, C., Julien, J., Douglas, K. L., Sensintaffar, J., Lu, N., Lee, K., et al. (2015) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.5b00054 · Cited by 253 · see citing works
Creighton, C. J., Hilger, A., Murthy, S., Rae, J. M., Chinnaiyan, A. M., & El‐Ashry, D. (2006) · Cancer Research · doi:10.1158/0008-5472.can-05-4363 · Cited by 243 · see citing works
Structural Basis for an Unexpected Mode of SERM-Mediated ER Antagonism
Wu, Y.-L., Yang, X., Ren, Z. M., McDonnell, D. P., Norris, J. D., Willson, T. M., & Greene, G. L. (2005) · Molecular Cell · doi:10.1016/j.molcel.2005.04.014 · Cited by 236 · see citing works
Self-citationMcDonnell, D. P., & Wardell, S. E. (2010) · Current Opinion in Pharmacology · doi:10.1016/j.coph.2010.09.007 · Cited by 204 · see citing works
Self-citationFulvestrant (Faslodex®)—How to Make a Good Drug Better
Robertson, J. F. R. (2007) · The Oncologist · doi:10.1634/theoncologist.12-7-774 · Cited by 164 · see citing works
Willson, T. M., Henke, B. R., Momtahen, T. M., Charifson, P. S., Batchelor, K. W., Lubahn, D. B., Moore, L. B., Oliver, B. B., Sauls, H. R., Triantafillou, J. A., et al. (1994) · Journal of Medicinal Chemistry · doi:10.1021/jm00037a002 · Cited by 146 · see citing works
Connor, C. E., Norris, J. D., Broadwater, G., Willson, T. M., Gottardis, M. M., Dewhirst, M. W., & McDonnell, D. P. (2001) · PubMed · Cited by 131 · see citing works
Self-citationComparative Analyses of Mechanistic Differences Among Antiestrogens1.
Wijayaratne, A., Nagel, S., Paige, L. A., Christensen, D., Norris, J., Fowlkes, D., & McDonnell, D. (1999) · Endocrinology · doi:10.1210/endo.140.12.7164 · Cited by 126 · see citing works
Self-citationWittmann, B. M., Sherk, A. B., & McDonnell, D. P. (2007) · Cancer Research · doi:10.1158/0008-5472.can-07-1590 · Cited by 126 · see citing works
Self-citationDuchnowska, R., Dziadziuszko, R., Trojanowski, T., Mandat, T. S., Och, W., Czartoryska-Arłukowicz, B., Radecka, B. S., Olszewski, W., Szubstarski, F., Kozłowski, W., et al. (2012) · Breast Cancer Research · doi:10.1186/bcr3244 · Cited by 104 · see citing works
Targeting Breast Cancer with CDK Inhibitors
Mayer, E. L. (2015) · Current Oncology Reports · doi:10.1007/s11912-015-0443-3 · Cited by 74 · see citing works
Deshmane, V., Krishnamurthy, S., Melemed, A. S., Peterson, P. M., & Buzdar, A. U. (2007) · Journal of Clinical Oncology · doi:10.1200/jco.2006.09.5992 · Cited by 70 · see citing works
Schafer, J. M., Lee, E. S., Dardes, R. C., Bentrem, D. J., O'Regan, R. M., Reyes, A. D. L., & Jordan, V. C. (2001) · PubMed · Cited by 52 · see citing works
Endocrine manipulation in advanced breast cancer: recent advances with SERM therapies.
Johnston, S. R. D. (2001) · PubMed · Cited by 46 · see citing works
Treatment of Breast Cancer Brain Metastases
Freedman, R. A., & Anders, C. K. (2011) · Current Breast Cancer Reports · doi:10.1007/s12609-011-0061-5 · Cited by 12 · see citing works
Flagged first, then by citations
1 of the 28 references couldn’t be matched to a known paper.
Research works printed but not linked: 6
- Johnston S. R., 2001, Clin. Cancer Res., 7, 4376s
- DeFriend D. J., 1994, Cancer Res., 54, 408
- Gottardis M. M., 1988, Cancer Res., 48, 812
- Connor C. E., 2001, Cancer Res., 61, 2917
- Schafer J. M., 2001, Clin. Cancer Res., 7, 2505
- Masamura S., 1995, J. Clin. Endocrinol. Metab., 80, 2918
Cited by
Sorted by citations
PROTAC targeted protein degraders: the past is prologue
Békés, M., Langley, D. R., & Crews, C. M. (2022) · Nature Reviews Drug Discovery · doi:10.1038/s41573-021-00371-6 · Cited by 3,395 · see citing works
Targeted protein degradation: mechanisms, strategies and application
Zhao, L., Zhao, J., Zhong, K., Tong, A., & Jia, D. (2022) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-022-00966-4 · Cited by 986 · see citing works
Zafar, A., Khatoon, S., Khan, M. J., Abu, J., & Naeem, A. (2025) · Discover Oncology · doi:10.1007/s12672-025-02198-8 · Cited by 676 · see citing works
Patel, H., & Bihani, T. (2017) · Pharmacology and Therapeutics · doi:10.1016/j.pharmthera.2017.12.012 · Cited by 423 · see citing works
Protac-Induced Protein Degradation in Drug Discovery: Breaking the Rules or Just Making New Ones?
Churcher, I. (2018) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.7b01272 · Cited by 491 · see citing works
Challenges and Opportunities in Cancer Drug Resistance
Ward, R. A., Fawell, S. E., Floc’h, N., Flemington, V., McKerrecher, D., & Smith, P. D. (2020) · Chemical Reviews · doi:10.1021/acs.chemrev.0c00383 · Cited by 454 · see citing works
Degradation of proteins by PROTACs and other strategies
Wang, Y., Jiang, X., Feng, F., Liu, W., & Sun, H. (2020) · Acta Pharmaceutica Sinica B · doi:10.1016/j.apsb.2019.08.001 · Cited by 335 · see citing works
Hu, J., Hu, B., Wang, M., Xu, F., Miao, B., Yang, C., Wang, M., Liu, Z., Hayes, D. F., Chinnaswamy, K., et al. (2019) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.8b01572 · Cited by 286 · see citing works
Sahayarayan, J. J., Kulanthaivel, S. R., Vidhyavathi, R., Nachiappan, M., Prabhu, D., Alfarraj, S. A., Arokiyaraj, S., & Daniel, A. N. (2020) · Saudi Journal of Biological Sciences · doi:10.1016/j.sjbs.2020.10.023 · Cited by 139 · see citing works
Hernándo, C., Ortega-Morillo, B., Tapia, M., Moragón, S., Martínez, M. T., Eroles, P., Garrido‐Cano, I., Adam‐Artigues, A., Lluch, A. M., Bermejo, B., et al. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms22157812 · Cited by 139 · see citing works
Endocrine resistance in hormone-responsive breast cancer: mechanisms and therapeutic strategies
Murphy, C. G., & Dickler, M. N. (2016) · Endocrine Related Cancer · doi:10.1530/erc-16-0121 · Cited by 133 · see citing works
Antibody-mediated delivery of chimeric protein degraders which target estrogen receptor alpha (ERα)
Dragovich, P. S., Adhikari, P., Blake, R. A., Blaquiere, N., Chen, J., Cheng, Y.-X., den Besten, W., Han, J., Hartman, S. J., He, J., et al. (2020) · Bioorganic & Medicinal Chemistry Letters · doi:10.1016/j.bmcl.2019.126907 · Cited by 120 · see citing works
Lu, Y., & Liu, W. (2020) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.0c00913 · Cited by 119 · see citing works
Mechanisms of endocrine therapy resistance in breast cancer
Rasha, F. A., Sharma, M., & Pruitt, K. (2021) · Molecular and Cellular Endocrinology · doi:10.1016/j.mce.2021.111322 · Cited by 115 · see citing works
Targeting the Estrogen Receptor for the Treatment of Breast Cancer: Recent Advances and Challenges
Rej, R. K., Thomas, J. E., Acharyya, R. K., Rae, J. M., & Wang, S. (2023) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.3c00136 · Cited by 115 · see citing works
Targeted protein knockdown using small molecule degraders
Raina, K., & Crews, C. M. (2017) · Current Opinion in Chemical Biology · doi:10.1016/j.cbpa.2017.05.016 · Cited by 111 · see citing works
Molecular Mechanisms of Endocrine Resistance in Estrogen-Receptor-Positive Breast Cancer
Belachew, E. B., & Sewasew, D. T. (2021) · Frontiers in Endocrinology · doi:10.3389/fendo.2021.599586 · Cited by 86 · see citing works
Using genetically incorporated unnatural amino acids to control protein functions in mammalian cells
Nödling, A. R., Spear, L. A., Williams, T. L., Luk, L. Y. P., & Tsai, Y. (2019) · Essays in Biochemistry · doi:10.1042/ebc20180042 · Cited by 109 · see citing works
Xie, S., Zhu, J., Li, J., Zhan, F., Yao, H., Xu, J., & Xu, S. (2023) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.3c00736 · Cited by 109 · see citing works
Lin, X., Xiang, H., & Luo, G. (2020) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2020.112689 · Cited by 100 · see citing works
Estrogens and the regulation of glucose metabolism
Alemany, M. (2021) · World Journal of Diabetes · doi:10.4239/wjd.v12.i10.1622 · Cited by 97 · see citing works
Yassemi, A., Kashanian, S., & Zhaleh, H. (2020) · Pharmaceutical Development and Technology · doi:10.1080/10837450.2019.1703739 · Cited by 94 · see citing works
Hamilton, E. P., Patel, M. R., Armstrong, A. C., Baird, R. D., Jhaveri, K. L., Hoch, M., Klinowska, T. C. M., Lindemann, J. P. O., Morgan, S. R., Schiavon, G., et al. (2018) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-17-3102 · Cited by 88 · see citing works
Xiong, R., Zhao, J., Gutgesell, L. M., Wang, Y., Lee, S., Karumudi, B., Zhao, H., Lu, Y., Tonetti, D. A., & Thatcher, G. R. J. (2017) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.6b01355 · Cited by 83 · see citing works
Recent development of targeted approaches for the treatment of breast cancer
Maruthanila, V. L., Elancheran, R., Kunnumakkara, A. B., Kabilan, S., & Kotoky, J. (2016) · Breast Cancer · doi:10.1007/s12282-016-0732-1 · Cited by 83 · see citing works
Antiestrogens: structure-activity relationships and use in breast cancer treatment
Traboulsi, T., Ezzy, M. E., Gleason, J., & Mader, S. (2016) · Journal of Molecular Endocrinology · doi:10.1530/jme-16-0024 · Cited by 64 · see citing works
Patel, H., Tao, N., Lee, K.-M., Huerta-Rosario, M., Arlt, H., Mullarkey, T. L., Troy, S. M., Arteaga, C. L., & Bihani, T. (2019) · Breast Cancer Research · doi:10.1186/s13058-019-1230-0 · Cited by 78 · see citing works
Wu, Q., Zhou, Q., Li, W., Ren, T., Zhang, X., & Yuan, L. (2022) · ACS Sensors · doi:10.1021/acssensors.2c01752 · Cited by 77 · see citing works
Cocce, K. J., Jasper, J. S., Desautels, T. K., Everett, L. J., Wardell, S. E., Westerling, T., Baldi, R. M., Wright, T. M., Tavares, K., Yllanes, A. P., et al. (2019) · Cell Reports · doi:10.1016/j.celrep.2019.09.032 · Cited by 76 · see citing works
Self-citationWang, Y., & Tang, S. (2022) · Cancer and Metastasis Reviews · doi:10.1007/s10555-022-10066-y · Cited by 76 · see citing works
Computer-Aided Ligand Discovery for Estrogen Receptor Alpha
Bafna, D., Ban, F., Rennie, P. S., Singh, K., & Cherkasov, A. R. (2020) · International Journal of Molecular Sciences · doi:10.3390/ijms21124193 · Cited by 73 · see citing works
Evolution of Cereblon-Mediated Protein Degradation as a Therapeutic Modality
Chamberlain, P. P., D’Agostino, L. A., Ellis, J. M., Hansen, J. D., Matyskiela, M. E., McDonald, J. J., Riggs, J. R., & Hamann, L. G. (2019) · ACS Medicinal Chemistry Letters · doi:10.1021/acsmedchemlett.9b00425 · Cited by 69 · see citing works
Targeted protein degradation in cancers: Orthodox PROTACs and beyond
Li, J., Chen, X., Lü, A., & Liang, C. (2023) · The Innovation · doi:10.1016/j.xinn.2023.100413 · Cited by 66 · see citing works
Farkas, S., Szabó, A., Hegyi, A., Török, B., Fazekas, C. L., Ernszt, D., Kovács, T., & Zelena, D. (2022) · Biomedicines · doi:10.3390/biomedicines10040861 · Cited by 69 · see citing works
Shagufta, Ahmad, I., Mathew, S., & Rahman, S. (2020) · RSC Medicinal Chemistry · doi:10.1039/c9md00570f · Cited by 64 · see citing works
Monomeric Targeted Protein Degraders
Hanan, E. J., Liang, J., Wang, X., Blake, R. A., Blaquiere, N., & Staben, S. T. (2020) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.0c00093 · Cited by 69 · see citing works
Novel endocrine therapies: What is next in estrogen receptor positive, HER2 negative breast cancer?
Corti, C., Angelis, C. D., Bianchini, G., Malorni, L., Giuliano, M., Hamilton, E. P., Jeselsohn, R. M., Jhaveri, K. L., Curigliano, G., & Criscitiello, C. (2023) · Cancer Treatment Reviews · doi:10.1016/j.ctrv.2023.102569 · Cited by 59 · see citing works
Raj, G. V., Sareddy, G. R., Ma, S., Lee, T.-K., Viswanadhapalli, S., Li, R., Liu, X., Murakami, S., Chen, C.-C., Lee, W.-R., et al. (2017) · eLife · doi:10.7554/elife.26857 · Cited by 58 · see citing works
Accelerating drug development in breast cancer: New frontiers for ER inhibition
Ferraro, E., Walsh, E. M., Tao, J. J., Chandarlapaty, S., & Jhaveri, K. L. (2022) · Cancer Treatment Reviews · doi:10.1016/j.ctrv.2022.102432 · Cited by 57 · see citing works
Current Trends in the Treatment of HR+/HER2+ Breast Cancer
Kay, C., Martínez-Pérez, C., Meehan, J., Gray, M., Webber, V. L., Dixon, J. M., & Turnbull, A. (2021) · Future Oncology · doi:10.2217/fon-2020-0504 · Cited by 59 · see citing works
Chen, Z., Hu, B., Rej, R. K., Wu, D., Acharyya, R. K., Wang, M., Xu, T., Lü, J., Metwally, H., Wang, Y., et al. (2023) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.3c01186 · Cited by 52 · see citing works
MiR-301a-3p Suppresses Estrogen Signaling by Directly Inhibiting ESR1 in ERα Positive Breast Cancer
Lettlová, S., Brynychová, V., Blecha, J., Vrána, D., Vondrusová, M., Souček, P., & Truksa, J. (2018) · Cellular Physiology and Biochemistry · doi:10.1159/000489687 · Cited by 50 · see citing works
A bright NIR-II fluorescent probe for breast carcinoma imaging and image-guided surgery
Zeng, X., Xie, L., Chen, D., Li, S., Nong, J., Wang, B., Tang, L., Li, Q., Li, Y., Deng, Z., et al. (2019) · Chemical Communications · doi:10.1039/c9cc07694h · Cited by 48 · see citing works
Burks, H. E., Abrams, T. J., Kirby, C. A., Baird, J., Fekete, A., Hamann, L. G., Kim, S., Lombardo, F., Loo, A. T., Lubicka, D., et al. (2017) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.6b01468 · Cited by 47 · see citing works
Self-citationLi, Y., Zhang, S., Zhang, J., Hu, Z., Yuan, X., Huang, J., Dong, C., Huang, S., & Zhou, H. (2019) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2019.03.058 · Cited by 47 · see citing works
Andreano, K. J., Wardell, S. E., Baker, J. G., Desautels, T. K., Baldi, R. M., Chao, C., Heetderks, K. A., Bae, Y., Xiong, R., Tonetti, D. A., et al. (2020) · Breast Cancer Research and Treatment · doi:10.1007/s10549-020-05575-9 · Cited by 47 · see citing works
Self-citationThe therapeutic potential of PROTACs
Benowitz, A. B., Jones, K. L., & Harling, J. D. (2020) · Expert Opinion on Therapeutic Patents · doi:10.1080/13543776.2021.1840553 · Cited by 47 · see citing works
Traboulsi, T., Ezzy, M. E., Dumeaux, V., Audemard, E. O., & Mader, S. (2018) · Oncogene · doi:10.1038/s41388-018-0468-9 · Cited by 44 · see citing works
Andreano, K. J., Baker, J. G., Park, S., Safi, R., Artham, S., Oesterreich, S., Jeselsohn, R. M., Brown, M. A., Sammons, S. L., Wardell, S. E., et al. (2020) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-19-1148 · Cited by 44 · see citing works
Self-citationNext-Generation Endocrine Therapies for Breast Cancer
McDonnell, D. P., Wardell, S. E., Chang, C., & Norris, J. D. (2021) · Journal of Clinical Oncology · doi:10.1200/jco.20.03565 · Cited by 42 · see citing works
Self-citationLiu, J., Zheng, S., Guo, S., Zhang, C., Zhong, Q., Zhang, Q., Ma, P., Skripnikova, E., Bratton, M. R., Wiese, T. E., et al. (2016) · ACS Medicinal Chemistry Letters · doi:10.1021/acsmedchemlett.6b00410 · Cited by 42 · see citing works
The hunt for a selective 17,20 lyase inhibitor; learning lessons from nature
Bird, I. M., & Abbott, D. H. (2016) · The Journal of Steroid Biochemistry and Molecular Biology · doi:10.1016/j.jsbmb.2016.04.021 · Cited by 43 · see citing works
Endocrine resistance and epigenetic reprogramming in estrogen receptor positive breast cancer
Dimitrakopoulos, F.-I. D., Kottorou, A. E., & Tzezou, A. (2021) · Cancer Letters · doi:10.1016/j.canlet.2021.05.030 · Cited by 38 · see citing works
Spinello, A., Martini, S., Berti, F., Pennati, M., Pavlin, M., Sgrignani, J., Grazioso, G., Colombo, G., Zaffaroni, N., & Magistrato, A. (2019) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2019.02.045 · Cited by 37 · see citing works
Mottamal, M., Kang, B.-R., Peng, X., & Wang, G. (2021) · ACS Omega · doi:10.1021/acsomega.0c06362 · Cited by 37 · see citing works
SERD-NHC-Au(I) complexes for dual targeting ER and TrxR to induce ICD in breast cancer
Lu, Y., Sheng, X., Liu, C., Liang, Z., Wang, X., Liu, L., Wen, Z., Yang, Z., Du, Q., & Liu, W. (2023) · Pharmacological Research · doi:10.1016/j.phrs.2023.106731 · Cited by 37 · see citing works
4-(1,2-diarylbut-1-en-1-yl)isobutyranilide derivatives as inhibitors of topoisomerase II
Christodoulou, M. S., Zarate, M., Ricci, F., Damia, G. L. M., Pieraccini, S., Dapiaggi, F., Sironi, M., Presti, L. L., García‐Argáez, A. N., Via, L. D., et al. (2016) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2016.03.090 · Cited by 36 · see citing works
Min, J., Guillen, V. S., Sharma, A., Zhao, Y., Ziegler, Y., Gong, P., Mayne, C. G., Srinivasan, S., Kim, S. H., Carlson, K. E., et al. (2017) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.7b00585 · Cited by 35 · see citing works
Busonero, C., Leone, S., Bartoloni, S., & Acconcia, F. (2018) · Molecular and Cellular Endocrinology · doi:10.1016/j.mce.2018.10.020 · Cited by 34 · see citing works
Current and emerging estrogen receptor-targeted therapies for the treatment of breast cancer
Haines, C. N., Wardell, S. E., & McDonnell, D. P. (2021) · Essays in Biochemistry · doi:10.1042/ebc20200174 · Cited by 34 · see citing works
Self-citationHe, M., Ning, W., Hu, Z., Huang, J., Dong, C., & Zhou, H. (2020) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2020.112281 · Cited by 33 · see citing works
Liang, J., Blake, R. A., Chang, J. H., Friedman, L. S., Goodacre, S. C., Hartman, S. J., Ingalla, E., Kiefer, J. R., Kleinheinz, T., Labadie, S. S., et al. (2020) · ACS Medicinal Chemistry Letters · doi:10.1021/acsmedchemlett.0c00224 · Cited by 33 · see citing works
Comparative biomarker analysis of PALOMA-2/3 trials for palbociclib
Zhu, Z., Turner, N. C., Loi, S., André, F., Martín, M., Dieras, V. C., Gelmon, K. A., Harbeck, N., Zhang, C., Cao, J. Q., et al. (2022) · npj Precision Oncology · doi:10.1038/s41698-022-00297-1 · Cited by 31 · see citing works
The protective role of estrogen and its receptors in gentamicin-induced acute kidney injury in rats
El-Lateef, S. M. A., El-Sayed, E.-S. M., Mansour, A. M., & Salama, S. A. (2019) · Life Sciences · doi:10.1016/j.lfs.2019.117082 · Cited by 31 · see citing works
Estrogen signaling suppresses tumor-associated tissue eosinophilia to promote breast tumor growth
Artham, S., Juras, P. K., Goyal, A., Chakraborty, P., Byemerwa, J. K., Liu, S., Wardell, S. E., Chakraborty, B., Crowder, D., Lim, F., et al. (2024) · Science Advances · doi:10.1126/sciadv.adp2442 · Cited by 30 · see citing works
Self-citationIn Silico Drug Design of Anti-Breast Cancer Agents
Rajagopal, K., Kalusalingam, A., Bharathidasan, A. R., Sivaprakash, A., Shanmugam, K., Sundaramoorthy, M., & Byran, G. (2023) · Molecules · doi:10.3390/molecules28104175 · Cited by 29 · see citing works
Ferro, A., Campora, M., Caldara, A., Lisi, D. D., Lorenzi, M., Monteverdi, S., Mihai, R., Bisio, A., Dipasquale, M., Caffo, O., et al. (2024) · Journal of Clinical Medicine · doi:10.3390/jcm13123611 · Cited by 31 · see citing works
Protein degradation: a validated therapeutic strategy with exciting prospects
Lebraud, H., & Heightman, T. D. (2017) · Essays in Biochemistry · doi:10.1042/ebc20170030 · Cited by 29 · see citing works
The Network of Angiotensin Receptors in Breast Cancer
Acconcia, F. (2020) · Cells · doi:10.3390/cells9061336 · Cited by 28 · see citing works
Wang, Y., Min, J., Deng, X., Feng, T., Hu, H., Guo, X., Cheng, Y., Xie, B., Yang, Y., Chen, C.-C., et al. (2023) · Acta Pharmaceutica Sinica B · doi:10.1016/j.apsb.2023.05.005 · Cited by 28 · see citing works
Busonero, C., Leone, S., & Acconcia, F. (2017) · Cellular Oncology · doi:10.1007/s13402-017-0322-z · Cited by 28 · see citing works
Nox1 downregulators: A new class of therapeutics
Barton, M., Meyer, M. R., & Prossnitz, E. R. (2019) · Steroids · doi:10.1016/j.steroids.2019.108494 · Cited by 28 · see citing works
Heitel, P. (2023) · Molecules · doi:10.3390/molecules28020690 · Cited by 27 · see citing works
Estrogen Receptor Alpha Mutations, Truncations, Heterodimers, and Therapies
Hancock, G. R., Gertz, J., Jeselsohn, R. M., & Fanning, S. W. (2024) · Endocrinology · doi:10.1210/endocr/bqae051 · Cited by 27 · see citing works
The Quest for Orally Available Selective Estrogen Receptor Degraders (SERDs)
Wang, L., & Sharma, A. (2020) · ChemMedChem · doi:10.1002/cmdc.202000473 · Cited by 27 · see citing works
Novel Estrogen Receptor-Targeted Agents for Breast Cancer
Shastry, M., & Hamilton, E. P. (2023) · Current Treatment Options in Oncology · doi:10.1007/s11864-023-01079-y · Cited by 27 · see citing works
GPER blockers as Nox downregulators: A new drug class to target chronic non-communicable diseases.
Meyer, M. R., & Barton, M. (2018) · Journal of Steroid Biochemistry and Molecular Biology · doi:10.1016/j.jsbmb.2017.03.019 · Cited by 27 · see citing works
Iorfida, M., Mazza, M., & Munzone, E. (2020) · Breast Cancer Targets and Therapy · doi:10.2147/bctt.s196240 · Cited by 29 · see citing works
Spinello, A., Ritacco, I., & Magistrato, A. (2019) · Expert Opinion on Drug Discovery · doi:10.1080/17460441.2019.1646245 · Cited by 25 · see citing works
Lu, Z., Cao, Y., Zhang, D., Meng, X., Guo, B., Kong, D., & Yang, Y. (2022) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.2c00008 · Cited by 25 · see citing works
Zheng, Y., Qiu, L., Hong, K., Dong, S., & Xu, X. (2017) · Chemistry - A European Journal · doi:10.1002/chem.201704759 · Cited by 25 · see citing works
Liang, J.-J., Yu, W., Yang, L., Xie, B., Qin, K.-M., Yin, Y., Yan, J., Gong, S., Liu, T.-Y., Zhou, H., et al. (2021) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2021.114081 · Cited by 24 · see citing works
Acharyya, R. K., Rej, R. K., Hu, B., Chen, Z., Wu, D., Lü, J., Metwally, H., McEachern, D., Wang, Y., Jiang, W., et al. (2024) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.4c01521 · Cited by 23 · see citing works
Research Progress on Bioactive Metal Complexes against ER-Positive Advanced Breast Cancer
Liang, Z., Liu, L., Zhou, Y., Liu, W., & Lu, Y. (2023) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.2c01458 · Cited by 23 · see citing works
Shao, P. (2021) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.1c01268 · Cited by 23 · see citing works
Ameya, P., Nathan, I., Konduri, S. D., George, C., Francis, A.-O., Mohd, A., Surendra, R., Madala, H. R., Basak, D., Mostofa, A. G. M., et al. (2016) · Journal of Biomedical Research · doi:10.7555/jbr.30.20160040 · Cited by 22 · see citing works
Induced degradation of protein kinases by bifunctional small molecules: a next-generation strategy
Groppe, J. C. (2019) · Expert Opinion on Drug Discovery · doi:10.1080/17460441.2019.1660641 · Cited by 22 · see citing works
Targeting Orthosteric and Allosteric Pockets of Aromatase via Dual-Mode Novel Azole Inhibitors
Caciolla, J., Spinello, A., Martini, S., Bisi, A., Zaffaroni, N., Gobbi, S., & Magistrato, A. (2020) · ACS Medicinal Chemistry Letters · doi:10.1021/acsmedchemlett.9b00591 · Cited by 21 · see citing works
Hancock, G. R., Young, K. S., Hosfield, D. J., Joiner, C., Sullivan, E., Yildiz, Y., Lainé, M., Greene, G. L., & Fanning, S. W. (2022) · npj Breast Cancer · doi:10.1038/s41523-022-00497-9 · Cited by 21 · see citing works
SERDs: a case study in targeted protein degradation
Wang, L., & Sharma, A. (2022) · Chemical Society Reviews · doi:10.1039/d2cs00117a · Cited by 20 · see citing works
Synthesis and evaluation of raloxifene derivatives as a selective estrogen receptor down-regulator
Shoda, T., Kato, M., Fujisato, T., Misawa, T., Demizu, Y., Inoue, H., Naito, M., & Kurihara, M. (2016) · Bioorganic & Medicinal Chemistry · doi:10.1016/j.bmc.2016.04.068 · Cited by 20 · see citing works
Estrogen receptor sensing in living cells by a high affinity turn-on fluorescent probe
Yang, L., Meng, Q., Hu, Z., Ning, W., Zheng, J., Dong, C., & Zhou, H. (2018) · Sensors and Actuators B Chemical · doi:10.1016/j.snb.2018.06.022 · Cited by 19 · see citing works
Palermo, A. F., Diennet, M., Ezzy, M. E., Williams, B. M., Cotnoir‐White, D., Mader, S., & Gleason, J. L. (2018) · Bioorganic & Medicinal Chemistry · doi:10.1016/j.bmc.2018.07.026 · Cited by 19 · see citing works
Urolithins: The Colon Microbiota Metabolites as Endocrine Modulators: Prospects and Perspectives
Vini, R., Azeez, J. M., Remadevi, V., Susmi, T. R., Ayswarya, R. S., Sujatha, A. S., Parvathy, M., Lathika, L. M., & Sreeja, S. (2022) · Frontiers in Nutrition · doi:10.3389/fnut.2021.800990 · Cited by 23 · see citing works
Fleisher, B., Brown, A. N., & Ait-Oudhia, S. (2017) · Pharmacological Research · doi:10.1016/j.phrs.2017.07.015 · Cited by 17 · see citing works
Kuznetsov, Y. V., Levina, I. S., Scherbakov, A. M., Andreeva, O. E., Fedyushkina, I. V., Dmitrenok, A. S., Shashkov, A. S., & Zavarzin, I. V. (2017) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2017.11.042 · Cited by 18 · see citing works
A comprehensive review on novel delivery approaches for exemestane
Chaturvedi, S., & Garg, A. (2022) · Journal of Drug Delivery Science and Technology · doi:10.1016/j.jddst.2022.103655 · Cited by 18 · see citing works
Wang, G. (2020) · Translational Cancer Research · doi:10.21037/tcr-20-2166 · Cited by 17 · see citing works
Guzzetti, S., & Gutierrez, P. M. (2023) · Journal of Pharmacokinetics and Pharmacodynamics · doi:10.1007/s10928-023-09857-9 · Cited by 18 · see citing works
Qiu, J., Bai, X., Zhang, W., Ma, M., Wang, W., Ye, L., Wang, H., Tian, J., & Yu, P. (2022) · Frontiers in Pharmacology · doi:10.3389/fphar.2022.853993 · Cited by 17 · see citing works
- Authors
- McDonnell, D. P., Wardell, S. E., & Norris, J. D.
- Affiliations
- Duke University (US)
- Corresponding author
- McDonnell, Donald P.
- Venue
- Journal of Medicinal Chemistry
- Publisher
- American Chemical Society (ACS)
- Published
- 2015-06-03
- Volume
- 58
- Issue
- 12
- Pages
- 4883-4887
- ISSN
- 0022-2623 (ISSN-L)
- 1520-4804
- PMC
- PMC4708081
- OpenAlex
- W2411335118
- Semantic Scholar
- 76771fb08cb3351347b0fb6ac913cde0e5a1f1c7
- Cited by
- 178
- References
- 28
- Citations by year
- 2026: 3 · 2025: 12 · 2024: 14 · 2023: 20 · 2022: 20 · 2021: 13 · 2020: 26 · 2019: 20 · 2018: 20 · 2017: 17 · 2016: 10 · 2015: 3
- Type
- journal article
- Language
- en
- Open access
- green
- www.ncbi.nlm.nih.gov
- Locations
- Journal of Medicinal Chemistry (publishedVersion)
- PubMed (publishedVersion)
- PubMed Central (acceptedVersion)
- Funders
- National Institute of Diabetes and Digestive and Kidney Diseases (R01DK048807, DK048807, R37DK048807)
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Genetics › Estrogen and related hormone effects
- Health Sciences › Medicine › Pulmonary and Respiratory Medicine › Advanced Breast Cancer Therapies
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Cancer Research › Breast Cancer Treatment Studies
- Keywords
- selective estrogen receptor downregulators, estrogen receptor alpha, breast cancer, endocrine therapy, tamoxifen resistance, aromatase inhibitor resistance, oral bioavailability, metastatic breast cancer, advanced breast cancer
- MeSH terms
- Animals, Breast, Breast Neoplasms, Female, Humans, Tamoxifen, Antineoplastic Agents, Hormonal, Selective Estrogen Receptor Modulators, Aromatase Inhibitors, Estrogen Receptor alpha, Drug Discovery
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Claims read by deepseek-v4.1-flash under definition version 3 (extract-v3) on 2026-10-10.
Classified by jev-1.13-20260917 (gold-guideline-v0.2) on 2026-10-10.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
